Addition of ublituximab to ibrutinib improves response in r/r CLLJune 7, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Severe health conditions decrease among childhood cancer survivorsJune 4, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Differences emerge in new guidelines for managing FN in kidsJune 3, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsTransplantationAMLALLAggressive Lymphomas
BLA for CAR T-cell therapy granted priority reviewMay 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Why fewer blood cancer patients receive hospice careMay 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAggressive Lymphomas
FDA grants priority review to NDA for copanlisibMay 18, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Compound could treat lymphoma, myelomaMay 17, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive Lymphomas
Intensive chemo upfront means DHL patients can skip HSCTMay 16, 2017Lymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive Lymphomas
HL survivors should be screened for CAD after chest irradiationMay 11, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Novel inhibitor proves ‘potent’ in hematologic malignanciesMay 9, 2017AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLALLMyelodysplastic SyndromeHodgkin Lymphoma
IV and SC rituximab produce similar results in FLMay 9, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
EC approves pembrolizumab for cHL patientsMay 8, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
BTK inhibitor staves off progression in CLLMay 6, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Pembrolizumab could change treatment paradigm, team saysApril 30, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
EMA recommends orphan status for drug for DLBCLApril 28, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
